Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Skeletal Muscle Relaxants: Adverse Effects

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...

Depolarizing Blockers: Mechanism of Action

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Use of Prokinetic Agents in Adult ICU Patients: An International Inception Cohort Study (PATIENCE).

Acta anaesthesiologica Scandinavica·2026

Same author

Ventilation strategies and outcomes after out-of-hospital cardiac arrest: protocol for a pre-planned sub-analysis of the STEPCARE trial.

BMJ open·2026

Same author

The Glasgow Coma Scale as a predictor of mortality in intensive care: relevance of underlying cause of impaired consciousness.

Journal of critical care·2026

Same author

Early Prediction of Neurological Outcome After Cardiac Arrest-Rationale and Design of the Prospective International Observational EARLY-NEURO, a STEPCARE Substudy.

Acta anaesthesiologica Scandinavica·2026

Same author

Severity of Illness and Mortality According to Time of Admission to Intensive Care.

Acta anaesthesiologica Scandinavica·2026

Same author

Characteristics of intensive care unit registries - findings from the Global Registry ICU Datasets (GRID) survey.

Critical care science·2026

Search research articles

Related Experiment Video

Updated: May 21, 2026

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models

Published on: March 8, 2024

[Interaction of donepezil with rocuronium].

Lauri Pautola¹, Matti Reinikainen

¹Pohjois-Karjalan keskussairaala, kirurgian klinikka.

Duodecim; Laaketieteellinen Aikakauskirja

|June 26, 2012

Summary

Donepezil, used for Alzheimer's disease, can weaken rocuronium bromide's muscle relaxation during anesthesia. Anesthesiologists should be aware of this drug interaction to ensure patient safety.

Area of Science:

Anesthesiology
Pharmacology
Neuroscience

Background:

Rocuronium bromide is a neuromuscular blocking agent used in general anesthesia.
Donepezil is an acetylcholinesterase inhibitor used to treat Alzheimer's disease.

Observation:

A case demonstrated that donepezil significantly diminished the muscle relaxant effects of rocuronium bromide.
This interaction highlights a potential clinical concern during anesthetic procedures.

Findings:

Donepezil's inhibition of acetylcholinesterase can interfere with neuromuscular blockade.
The observed potentiation of muscle relaxation reversal suggests a clinically relevant pharmacodynamic interaction.

Implications:

Anesthesiologists must consider concurrent use of donepezil and rocuronium.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Related Experiment Videos

Last Updated: May 21, 2026

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models

Published on: March 8, 2024

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

A pause in acetylcholinesterase inhibitor therapy before anesthesia may be prudent, though further data is needed.

Awareness of this interaction is crucial for maintaining safe intubation and surgical conditions.